论文部分内容阅读
目的:观察复方苦参注射液联合化疗对晚期胃癌临床疗效及肿瘤标志物的影响。方法:将120例晚期胃癌患者随机分为观察组和对照组,每组60例。对照组进行常规化疗:采用FOLFOX方案。观察组:在对照组化疗方案基础上,同时加用复方苦参注射液15 mL入0.9%NS250 mL静滴,每日1次,10 d为1个疗程。2～6个周期化疗进行疗效评价。结果:客观疗效,观察组和对照组有效率RR(CR+PR)分别为63.3%和43.1%,疾病控制率DCR(CR+PR+SD)分别为90%和74.1%,两组间有差异(P<0.05)。疼痛症状评估:观察组疼痛缓解率明显高于对照组(P<0.01)。肿瘤标志物:治疗前两组患者三项肿瘤标记物水平无明显差异。对照组治疗后CA72-4较治疗前下降有统计学意义,CA19-9、CEA虽有下降趋势但差异无统计学意义(P>0.05);观察组治疗后三项指标较治疗前下降有统计学意义(P<0.05)。结论:复方苦参注射液配合化疗治疗晚期胃癌,能增强化疗疗效,缓解疼痛,降低肿瘤标志物指标等作用。
Objective: To observe the effect of Compound Kushen Injection combined with chemotherapy on the clinical efficacy and tumor markers of advanced gastric cancer. Methods: 120 patients with advanced gastric cancer were randomly divided into observation group and control group, 60 cases in each group. Control group for conventional chemotherapy: the FOLFOX program. Observation group: On the basis of the chemotherapy in the control group, 15 mL of compound Kushen injection plus 0.9% NS250 mL intravenous infusion was given once daily for 10 days for one course of treatment. 2 ~ 6 cycles of chemotherapy for efficacy evaluation. Results: The objective response rate was 63.3% and 43.1% respectively in the observation group and the control group, and the rate of disease control was 90% and 74.1% respectively, with a difference between the two groups (P <0.05). Evaluation of pain symptoms: The pain relief rate in the observation group was significantly higher than that in the control group (P <0.01). Tumor markers: There was no significant difference in the levels of the three tumor markers in the two groups before treatment. The CA72-4 level in the control group decreased significantly compared with that before treatment, while the levels of CA19-9 and CEA had no statistical significance (P> 0.05). The three indexes of the observation group decreased after treatment Significance (P <0.05). Conclusion: Compound Kushen injection combined with chemotherapy in the treatment of advanced gastric cancer can enhance the curative effect, relieve pain and reduce the tumor markers.